These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 10901381)

  • 21. Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial.
    Martin J; Stribbling SM; Poon GK; Begent RH; Napier M; Sharma SK; Springer CJ
    Cancer Chemother Pharmacol; 1997; 40(3):189-201. PubMed ID: 9219501
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic gene-directed enzyme prodrug therapy of hepatocellular carcinoma using a targeted adenovirus armed with carboxypeptidase G2.
    Schepelmann S; Hallenbeck P; Ogilvie LM; Hedley D; Friedlos F; Martin J; Scanlon I; Hay C; Hawkins LK; Marais R; Springer CJ
    Cancer Res; 2005 Jun; 65(12):5003-8. PubMed ID: 15958540
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel fluorinated prodrugs for activation by carboxypeptidase G2 showing good in vivo antitumor activity in gene-directed enzyme prodrug therapy.
    Davies LC; Friedlos F; Hedley D; Martin J; Ogilvie LM; Scanlon IJ; Springer CJ
    J Med Chem; 2005 Aug; 48(16):5321-8. PubMed ID: 16078849
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adenovirus vector-mediated delivery of the prodrug-converting enzyme carboxypeptidase G2 in a secreted or GPI-anchored form: High-level expression of this active conditional cytotoxic enzyme at the plasma membrane.
    Cowen RL; Williams JC; Emery S; Blakey D; Darling JL; Lowenstein PR; Castro MG
    Cancer Gene Ther; 2002 Nov; 9(11):897-907. PubMed ID: 12386828
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody directed enzyme prodrug therapy (ADEPT): clinical report.
    Bagshawe KD; Sharma SK; Springer CJ; Antoniw P; Boden JA; Rogers GT; Burke PJ; Melton RG; Sherwood RF
    Dis Markers; 1991; 9(3-4):233-8. PubMed ID: 1813213
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antitumor effects of an antibody-carboxypeptidase G2 conjugate in combination with a benzoic acid mustard prodrug.
    Blakey DC; Valcaccia BE; East S; Wright AF; Boyle FT; Springer CJ; Burke PJ; Melton RG; Bagshawe KD
    Cell Biophys; 1993; 22(1-3):1-8. PubMed ID: 7889535
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Coupling of a Novel TIMP3 Peptide to Carboxypeptidase G2 for Pro-Drug Activation at the Tumour Site.
    Aldughaim MS; Alsaffar F; Barker MD
    Molecules; 2021 Jan; 26(3):. PubMed ID: 33504102
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs.
    Blakey DC; Davies DH; Dowell RI; East SJ; Burke PJ; Sharma SK; Springer CJ; Mauger AB; Melton RG
    Br J Cancer; 1995 Nov; 72(5):1083-8. PubMed ID: 7577451
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Three new prodrugs for suicide gene therapy using carboxypeptidase G2 elicit bystander efficacy in two xenograft models.
    Friedlos F; Davies L; Scanlon I; Ogilvie LM; Martin J; Stribbling SM; Spooner RA; Niculescu-Duvaz I; Marais R; Springer CJ
    Cancer Res; 2002 Mar; 62(6):1724-9. PubMed ID: 11912146
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of triazene prodrugs for ADEPT strategy: new insights into drug delivery system based on carboxypeptidase G2 activation.
    Capucha V; Mendes E; Francisco AP; Perry MJ
    Bioorg Med Chem Lett; 2012 Nov; 22(22):6903-8. PubMed ID: 23041157
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sustained tumor regression of human colorectal cancer xenografts using a multifunctional mannosylated fusion protein in antibody-directed enzyme prodrug therapy.
    Sharma SK; Pedley RB; Bhatia J; Boxer GM; El-Emir E; Qureshi U; Tolner B; Lowe H; Michael NP; Minton N; Begent RH; Chester KA
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):814-25. PubMed ID: 15701872
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug.
    Mayer A; Francis RJ; Sharma SK; Tolner B; Springer CJ; Martin J; Boxer GM; Bell J; Green AJ; Hartley JA; Cruickshank C; Wren J; Chester KA; Begent RH
    Clin Cancer Res; 2006 Nov; 12(21):6509-16. PubMed ID: 17085666
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination.
    Marais R; Spooner RA; Light Y; Martin J; Springer CJ
    Cancer Res; 1996 Oct; 56(20):4735-42. PubMed ID: 8840992
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Self-immolative anthracycline prodrugs for suicide gene therapy.
    Niculescu-Duvaz I; Niculescu-Duvaz D; Friedlos F; Spooner R; Martin J; Marais R; Springer CJ
    J Med Chem; 1999 Jul; 42(13):2485-9. PubMed ID: 10395490
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy.
    Hay MP; Anderson RF; Ferry DM; Wilson WR; Denny WA
    J Med Chem; 2003 Dec; 46(25):5533-45. PubMed ID: 14640560
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody directed enzyme prodrug therapy (ADEPT): a three phase system.
    Sharma SK; Bagshawe KD; Springer CJ; Burke PJ; Rogers GT; Boden JA; Antoniw P; Melton RG; Sherwood RF
    Dis Markers; 1991; 9(3-4):225-31. PubMed ID: 1813212
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy.
    Atwell GJ; Yang S; Pruijn FB; Pullen SM; Hogg A; Patterson AV; Wilson WR; Denny WA
    J Med Chem; 2007 Mar; 50(6):1197-212. PubMed ID: 17326614
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Attenuated Salmonella targets prodrug activating enzyme carboxypeptidase G2 to mouse melanoma and human breast and colon carcinomas for effective suicide gene therapy.
    Friedlos F; Lehouritis P; Ogilvie L; Hedley D; Davies L; Bermudes D; King I; Martin J; Marais R; Springer CJ
    Clin Cancer Res; 2008 Jul; 14(13):4259-66. PubMed ID: 18594008
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Toward antibody-directed "abzyme" prodrug therapy, ADAPT: carbamate prodrug activation by a catalytic antibody and its in vitro application to human tumor cell killing.
    Wentworth P; Datta A; Blakey D; Boyle T; Partridge LJ; Blackburn GM
    Proc Natl Acad Sci U S A; 1996 Jan; 93(2):799-803. PubMed ID: 8570638
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of glutathione depletion on inhibition of cell cycle progression and induction of apoptosis by melphalan (L-phenylalanine mustard) in human colorectal cancer cells.
    Vahrmeijer AL; van Dierendonck JH; Schutrups J; van de Velde CJ; Mulder GJ
    Biochem Pharmacol; 1999 Aug; 58(4):655-64. PubMed ID: 10413303
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.